Drugs / Lutetium (177Lu) DGUL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07244393 | Dec 2025 → Apr 2029 expected | prostate carcinoma | Cellbion Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium (177Lu) DGUL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07244393 ↗ |